Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

INTRODUCTION: KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. METHODS: In the Biomarkers France study, 4894 KRAS mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruppert, Anne-Marie, Beau-Faller, Michèle, Debieuvre, Didier, Ouafik, L’Houcine, Westeel, Virginie, Rouquette, Isabelle, Mazières, Julien, Bringuier, Pierre-Paul, Monnet, Isabelle, Escande, Fabienne, Ricordel, Charles, Merlio, Jean-Philippe, Janicot, Henri, Lemoine, Antoinette, Foucher, Pascal, Poudenx, Michel, Morin, Franck, Langlais, Alexandra, Souquet, Pierre-Jean, Barlesi, Fabrice, Wislez, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474404/
https://www.ncbi.nlm.nih.gov/pubmed/34589947
http://dx.doi.org/10.1016/j.jtocrr.2020.100052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474404/
https://www.ncbi.nlm.nih.gov/pubmed/34589947
http://dx.doi.org/10.1016/j.jtocrr.2020.100052

Ejemplares similares